04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
18:09 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggesting inhibiting LOXL2 could help treat metastatic breast cancer. In a mouse model of breast cancer, mammary gland-specific knockout of LOXL2 decreased lung metastatic burden and the number circulating tumor...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
23:33 , Apr 14, 2017 |  BioCentury  |  Product Development

New endpoints in NASH

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs....
00:51 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample and mouse studies suggest inhibiting LOXL2 could help treat heart failure. LOXL2 levels were higher in serum samples from heart failure patients and cardiac tissue samples from cardiomyopathy patients than...
20:24 , Dec 9, 2016 |  BC Week In Review  |  Company News

PharmAkea, Celgene deal

PharmAkea and Celgene extended by nine months a deal to use PharmAkea's drug discovery platform to discover and develop small molecules to treat fibrotic diseases. Celgene committed $9 million to PharmAkea to extend the deal....
19:58 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

Simtuzumab: Development discontinued

Gilead said it discontinued development of subcutaneous simtuzumab for all indications after data from 3 double-blind, placebo-controlled, international Phase IIb trials showed a lack of efficacy. The trials evaluated simtuzumab to treat PSC; to treat...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

Selonsertib: Phase II data

Top-line data from the open-label, North American Phase II Study GS-US-384-1497 in 67 evaluable patients with NASH and moderate to severe liver fibrosis showed that once-daily 6 and 18 mg selonsertib with or without once-weekly...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

Simtuzumab: Phase II data

Top-line data from the open-label, North American Phase II Study GS-US-384-1497 in 67 evaluable patients with NASH and moderate to severe liver fibrosis showed that once-daily 6 and 18 mg selonsertib with or without once-weekly...
07:00 , Oct 20, 2016 |  BC Extra  |  Clinical News

Gilead's selonsertib heading for Phase III NASH trial

Gilead Sciences Inc. (NASDAQ:GILD) said anti-fibrotic activity shown in a Phase II study of selonsertib ( GS-4997 ) to treat non-alcoholic steatohepatitis warrants advancement of the compound into Phase III testing in the indication. Among...